ArticleBMJ open2024
Global epidemiological profile in nasopharyngeal carcinoma: a prediction study.
Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiotherapy-Induced Otitis Media With Effusion in Nasopharyngeal Carcinoma: A Meta-Analysis.The Laryngoscope · 2026Pooled it
- Epstein-Barr Virus-Mediated Apoptosis Evasion in Epithelial Malignancies: Molecular Mechanisms and Therapeutic Implications.Biology · 2026Review
- Correlation analysis of gut microbiota and metabolites in gastric cancer patients in plateau areas based on multi-omics technologies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Preliminary Findings on the Predictive Value of Hematologic Inflammatory Indices for Survival in Treatment-Naïve Non-Metastatic Nasopharyngeal Carcinoma: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- A bibliometric analysis of the evolution of nanotechnology research in precision theranostics for nasopharyngeal carcinoma.Discover nano · 2026Article
- Therapeutic Innovations in Nasopharyngeal Carcinoma: Current Strategies and Emerging Perspectives.Life (Basel, Switzerland) · 2026Review
- Therapeutic Vaccines for Head and Neck Squamous Cell Carcinoma and Nasopharyngeal Carcinoma.Vaccines · 2026Review
- Integrated primary tumor and all metastatic lymph nodes radiomics from 18 F-FDG PET/CT for precise M1 subclassification in nasopharyngeal carcinoma.BMC cancer · 2026Article
- Race, Ethnicity, and Nasopharyngeal Cancer Subtypes in the US.JAMA network open · 2026Article
- Results of applying the 9th edition TNM classification in the staging assessment of nasopharyngeal carcinoma: first data in Vietnam.Frontiers in oncology · 2026Article
- Oral Metronomic Chemotherapy in Nasopharyngeal Carcinoma with Radiotherapy Interruptions: A Lesson Learned from the Lockdown Due to COVID-19.Recent patents on anti-cancer drug discovery · 2026Article
- Article
- Construction and validation of a machine learning model to predict the risk of nasopharyngeal carcinoma using multimodal clinical data: a single-center, retrospective study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Untargeted metabolomics analysis of metabolite changes in gastric cancer patients from plateau regions.World journal of gastrointestinal oncology · 2025Article
- Global and regional burden of nasopharyngeal cancer in older adults attributable to smoking and high alcohol use from 1990 to 2021.Frontiers in public health · 2025Article
- Association of the IL-10 and IL-18 polymorphisms with nasopharyngeal carcinoma risk.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study delineates the global nasopharyngeal carcinoma's (NPC) incidence and mortality across 185 countries in 2020 and projects the disease's burden by 2040.
designA prediction study.
settingCountries within the 20 world regions.
participantsGlobal NPC population. PRIMARY AND SECONDARY OUTCOME MEASURES: The estimated counts of NPC cases and deaths were retrieved from the GLOBOCAN 2020 database. Age-standardised incidence rates (ASIR) and age-standardised death rates (ASDR) were computed. Projections for NPC by 2040 were derived from global population forecasts.
resultsIn the year 2020, East Asia emerged as the epicentre of both NPC incidences and mortalities, encompassing 49.39% (65 866 of the total 133 354 cases) and 45.56% (36 453 of the total 80 008 deaths), respectively, with China's contribution being the most substantial (46.82% of cases and 43.50% of deaths). The disparity between genders was notable, as the ASIR and ASDR for males were approximately triple those observed in females. The incidence exhibited regional diversity, with South-Eastern Asia and East Asia recording the highest ASIR for males and females (7.7 and 2.5, and 3.9 and 1.5 per 100 000 person-years, respectively). Similarly, South-Eastern Asia also reported the highest ASDR for both genders (5.4 and 1.5 per 100 000 person-years, respectively). Projections for 2040 anticipate a rise in annual cases and deaths to 179 476 (indicating a 34.58% increase from 2020) and 113 851 (reflecting a 42.29% increase), respectively. Further analysis revealed a correlation between the Human Development Index and disease burden.
conclusionsNPC, primarily impacting East Asia and predominantly affecting men, is poised for a significant increase in incidence and mortality by 2040, especially in Asia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.